⌘K
Loading ticker…
Dianthus Therapeutics, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Dianthus Therapeutics, Inc. Common Stock (DNTH) has a 3-month relative strength percentile of 66 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 88. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 6.6%, relative volume 4.54×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
66 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
DNTH is in a stage 2 uptrend, week 1. Currently in a 50-day base; basing ADR 5.5% (broad 6.2%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 10.1% / 61.6%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
DNTH is held by 6 ETFs as of Mar 2026. Top owner: VTI at 0.01% weight, $131M notional. Top 3 carry $254M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.01% | $131M |
| IWMiShares Russell 2000 ETF | 0.10% | $73M |
| XBIState Street SPDR S&P Biotech ETF | 0.66% | $49M |
| VXFVanguard Extended Market ETF | 0.04% | $35M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $4M |
| IWOiShares Russell 2000 Growth ETF | 0.02% | $2M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DNTH Jan avg: 37.95% median: 29.56% win: 100% σ: 41.19% n: 3 2023-09-13 → 2026-05-29 | DNTH Feb avg: 10.38% median: 3.37% win: 67% σ: 17.46% n: 3 2023-09-13 → 2026-05-29 | DNTH Mar avg: 19.08% median: 21.21% win: 67% σ: 34.09% n: 3 2023-09-13 → 2026-05-29 | DNTH Apr avg: -1.25% median: 4.62% win: 67% σ: 25.16% n: 3 2023-09-13 → 2026-05-29 | DNTH May avg: -4.42% median: 1.22% win: 67% σ: 14.05% n: 3 2023-09-13 → 2026-05-29 | DNTH Jun avg: 13.44% median: 13.44% win: 100% σ: 8.93% n: 2 2023-09-13 → 2026-05-29 (current) | DNTH Jul avg: 13.01% median: 13.01% win: 100% σ: 2.91% n: 2 2023-09-13 → 2026-05-29 | DNTH Aug avg: 5.42% median: 5.42% win: 50% σ: 12.18% n: 2 2023-09-13 → 2026-05-29 | DNTH Sep avg: 28.73% median: 24.27% win: 67% σ: 36.20% n: 3 2023-09-13 → 2026-05-29 | DNTH Oct avg: -7.19% median: -11.11% win: 33% σ: 7.76% n: 3 2023-09-13 → 2026-05-29 | DNTH Nov avg: 1.67% median: -6.83% win: 33% σ: 21.13% n: 3 2023-09-13 → 2026-05-29 | DNTH Dec avg: -7.47% median: -6.98% win: 0% σ: 1.48% n: 3 2023-09-13 → 2026-05-29 |